(Q54459547)

30 May 2018

title

Key findings towards optimising adalimumab treatment: the concentration-effect curve. (English)

1 reference

30 May 2018

0 references

Mieke F Pouw

1

1 reference

30 May 2018

Charlotte L Krieckaert

2

1 reference

30 May 2018

Michael T Nurmohamed

3

1 reference

30 May 2018

Desiree van der Kleij

4

1 reference

30 May 2018

Lucien Aarden

5

1 reference

30 May 2018

Theo Rispens

6

1 reference

30 May 2018

Gertjan Wolbink

7

1 reference

30 May 2018

language of work or name

English

0 references

publication date

10 December 2013

1 reference

30 May 2018

Annals of the Rheumatic Diseases

published in

1 reference

30 May 2018

volume

74

1 reference

30 May 2018

issue

3

1 reference

30 May 2018

page(s)

513-518

1 reference

30 May 2018

Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7

cites work

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204172

Update on D2E7: a fully human anti-tumour necrosis factor alpha monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204172

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204172

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204172

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204172

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204172

Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204172

Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204172

Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204172

Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204172

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204172

10.1136/ANNRHEUMDIS-2013-204172

21 January 2018

Identifiers

DOI

1 reference

30 May 2018

1 reference

30 May 2018